


Supplemental Figure 1. HIV screening testing schema.



Supplemental Figure 1 legend

Samples from participants who were virally suppressed on ART for ≥4 years were tested with two HIV rapid tests (the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test [Orasure Technologies, Inc, Bethlehem, PA] and the Uni-Gold Recombigen HIV-1/2 Test [Trinity Biotech, Wicklow, Ireland]), two 4th-generation immunoassays (the ARCHITECT HIV Ag/Ab Combo assay [Abbott Laboratories, Abbott Park, IL] and the GS HIV Combo Ag/Ab EIA [Bio-Rad Laboratories, Redmond, WA]), and the GS HIV-1 Western blot (Bio-Rad Laboratories, Redmond, WA).

Supplemental Figure 2. Representative examples of weakly-reactive HIV rapid test results.

A



R

R*

R**

R***

B



R

R*

R**

R***

Supplemental Figure 2 legend

Dilution panels were used to guide interpretation of the strength of the HIV rapid test results. The figure shows representative examples of the HIV rapid test bands that were scored as reactive (R) or weakly-reactive (R*: faint band; R**: very faint band; and R***: extremely faint band). Panel A shows results obtained with the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test. Panel B shows results obtained with the Uni-Gold Recombigen HIV-1/2 Test.

Supplemental Table. HIV rapid test results from 10 participants who had a non-reactive or weakly-reactive rapid test at follow-up (≥4 years on suppressive ART).

| # | Arm | Study visit | Time on ART | Rapid OQ | Rapid UG | # | Arm | Study visit | Time on ART | Rapid OQ | Rapid UG |
|---|-------|-------------|-------------|----------|----------|-----------|---------|-------------|-------------|----------|----------|
| 1 | Early | Baseline | 0 | R | R | 6 | Early | Baseline | 0 | R | R |
| | | Interim | 1.0 | R* | R | | | Interim | 1.0 | R* | R |
| | | Interim | 1.9 | R** | R | | | Interim | 2.0 | R*** | R |
| | | Interim | 3.0 | R*** | R | | | Interim | 3.0 | R*** | R |
| | | Interim | 3.9 | R*** | R | | | Interim | 3.9 | R*** | R |
| | | Follow-up | 4.9 | R** | R | | | Follow-up | 4.9 | R*** | R |
| 2 | Early | Baseline | 0 | R | R | 7 | Early | Baseline | 0 | R | R |
| | | Interim | 1.0 | R | R | | | Interim | 1.0 | R*** | R* |
| | | Interim | 2.0 | R* | R | | | Interim | 1.9 | R* | R |
| | | Interim | 3.0 | R* | R | | | Interim | 3.0 | R* | R* |
| | | Interim | 3.9 | R* | R | | | Follow-up | 4.0 | R*** | R |
| | | Follow-up | 4.9 | R** | R | 8 | Delayed | Baseline | 0 | R | R |
| 3 | Early | Baseline | 0.0 | R | R | | | Interim | 0.9 | R | R |
| | | Interim | 1.0 | R | R | | | Interim | 1.9 | R | R |
| | | Interim | 2.0 | R | R | | | Interim | 2.9 | R | R |
| | | Interim | 3.0 | R** | R* | | | Interim | 3.8 | R* | R |
| | | Interim | 3.9 | R** | R | Follow-up | 4.6 | R** | R | | |
| | | Interim | 4.9 | R** | R* | 9 | Delayed | Baseline | 0 | R | R |
| | | Interim | 5.9 | R*** | R* | | | Interim | 1.2 | R | R |
| | | Interim | 6.9 | R*** | R** | | | Interim | 2.1 | R | R |
| | | Interim | 7.9 | R*** | R** | | | Interim | 3.1 | R* | R |
| | | Follow-up | 8.9 | R*** | R* | | | Interim | 4.1 | R* | R |
| 4 | Early | Baseline | 0 | R | R | 10 | Delayed | Baseline | 0 | R | R |
| | | Interim | 1.0 | R | R* | | | Interim | 1.0 | R | R |
| | | Interim | 2.0 | R** | R** | | | Interim | 2.0 | R | R |
| | | Interim | 3.0 | R** | R* | | | Interim | 3.0 | R | R |
| | | Interim | 4.0 | R** | R* | | | Interim | 3.9 | R | R |
| | | Follow-up | 5.0 | R*** | R* | | | Follow-up | 4.4 | NR | NR |
| 5 | Early | Baseline | 0 | R | R | | | | | | |
| | | Interim | 1.0 | R | R** | | | | | | |
| | | Interim | 2.0 | R** | NR | | | | | | |
| | | Interim | 3.0 | R** | R* | | | | | | |
| | | Interim | 3.9 | R*** | NR | | | | | | |
| | | Follow-up | 4.9 | R*** | R** | | | | | | |

Supplemental Table footnotes

The table shows HIV rapid test results for study visits from the visit prior to initiation of antiretroviral therapy (ART, baseline) to a visit ≥ 4 years on suppressive ART (follow-up). Results are shown for 10 cases where the participant had a non-reactive or weakly reactive HIV rapid test result at follow-up (Cases #1-10). Time on ART indicates the number of years between ART initiation and sample collection. The strength of the test band was graded using dilution controls (R: reactive, R*: weakly-reactive with a faint band; R**: weakly-reactive with a very faint band; R***: weakly-reactive with an extremely faint band; NR: non-reactive; see Supplemental Figure 1).

Abbreviations: OQ: OraQuick; UG: Uni-Gold.